PDCD1 and melanoma: Subsequent clinical development has established PD-1/PD-L1 axis inhibitors as clinically validated therapeutic agents across multiple solid tumor indications, revolutionizing treatment paradigms for malignancies such as melanoma, non-small cell lung cancer, and renal cell carcinoma [133–137].